• Cleveland BioLabs Inc., of Buffalo, N.Y., said it submitted a proposal to the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services for funding to complete the development steps needed for FDA licensure of Entolimod as a medical radiation countermeasure.